Adolor Corporation (ADLR)
Q1 2010 Earnings Call Transcript
April 28, 2010 8:45 am ET
Stephen Webster – SVP, Finance and CFO
Mike Dougherty – President and CEO
Eliseo Salinas – SVP, R&D and Chief Medical Officer
Ling Wang – Brean Murray
Jeremiah Shepard – Wedbush
Welcome to the Adolor conference call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session to follow. Please be advised that this call is being taped at the request of Adolor. At this time, I would like to introduce your host for today's call, Stephen Webster, Senior Vice President of Finance and Chief Financial Officer at Adolor. Please go ahead.
Thank you, operator. Good morning everyone. Today, we will provide an update of our operations and review our financial results for the quarter-ended March 31st. Before we begin, let me remind you that certain statements on this call may be forward-looking and are subject to risks and uncertainties associated with our business. These statements may concern, among other things, guidance as to future revenue from ENTEREG or anticipated levels of our cash and investments, our operations and prospects, transactions, intellectual property, litigation, the development of pharmaceutical products, clinical trials and any potential approval of our product candidates.
Additional information and risk factors affecting the company's business and financial prospects and other factors that could cause Adolor's actual performance to vary from our current expectations are available in our SEC filings. Investors with further questions should contact me at 484-595-1500. This conference call is being webcast via the Adolor home page and it will be archived for one week after the call. Now, I'll turn it over to Mike Dougherty, our President and Chief Executive Officer.